Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).

被引：1
|
作者：
Sznol, Mario
Kluger, Harriet M.
Callahan, Margaret K.
Postow, Michael Andrew
Gordon, Ruth Ann
Segal, Neil Howard
Rizvi, Naiyer A.
Lesokhin, Alexander M.
Atkins, Michael B.
Kirkwood, John M.
Burke, Matthew M.
Ralabate, Amanda L.
Rivera, Angel L.
Kronenberg, Stephanie Anne
Agunwamba, Blessing
Feely, William
Hong, Quan
Krishnan, Suba
Gupta, Ashok Kumar
Wolchok, Jedd D.
机构：
[1] Yale Canc Ctr, New Haven, CT USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[4] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[5] Bristol Myers Squibb, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA9003
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL).
    Hodi, F. Stephen
    Sznol, Mario
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne Louise
    Wigginton, Jon
    McDonald, Dan
    Kollia, Georgia
    Gupta, Ashok Kumar
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.
    Segal, Neil Howard
    Hodi, F. Stephen
    Sanborn, Rachel E.
    Gajewski, Thomas
    Wolchok, Jedd D.
    Urba, Walter John
    Fox, Bernard A.
    Topallan, Suzanne Louise
    Pardoll, Drew M.
    Kollia, Georgia
    McDonald, Dan
    Kim, Su Young
    Sharfman, William Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice in advanced melanoma patients progressing post anti-CTLA-4 therapy.
    Chmielowski, Bartosz
    Hamid, Omid
    Minor, David R.
    D'Angelo, Sandra P.
    Pennock, Gregory K.
    Grossmann, Kenneth
    Ascierto, Paolo Antonio
    Daud, Adil
    Dummer, Reinhard
    Hodi, F. Stephen
    Lebbe, Celeste
    Robert, Caroline
    Sosman, Jeffrey Alan
    Yang, Arvin
    Lambert, Alexandre
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] A phase 3 comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients with advanced or metastatic renal cell carcinoma (mRCC) previously treated with anti-angiogenic therapy
    Motzer, R. J.
    Bono, P.
    Tomita, Y.
    Ravaud, A.
    Waxman, I.
    Gore, M. E.
    BJU INTERNATIONAL, 2013, 112 : 10 - 10
  • [45] EFFICACY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SUBPOPULATION RESPONSE ANALYSIS IN A PHASE 1 TRIAL
    Gettinger, Scott
    Horn, Leora
    Antonia, Scott J.
    Spigel, David R.
    Gandhi, Leena
    Sequist, Lecia V.
    Sankar, Vindira
    Ahlers, Christoph M.
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok
    Brahmer, Julie R.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S909 - S909
  • [46] Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC)
    Gettinger, S.
    Chow, L. Q.
    Borghaei, H.
    Shen, Y.
    Harbison, C.
    Chen, A. C.
    Rizvi, N. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S34 - S35
  • [47] First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status
    Rizvi, N. A.
    Shepherd, F. A.
    Antonia, S. J.
    Brahmer, J. R.
    Chow, L. Q.
    Goldman, J.
    Juergens, R.
    Borghaei, H.
    Ready, N. E.
    Gerber, D. E.
    Shen, Y.
    Harbison, C.
    Chen, A. C.
    Gettinger, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S31 - S31
  • [48] NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC): OVERALL SURVIVAL AND LONG-TERM SAFETY IN A PHASE 1 TRIAL
    Brahmer, Julie R.
    Horn, Leora
    Antonia, Scott J.
    Spigel, David
    Gandhi, Leena
    Sequist, Lecia V.
    Sankar, Vindira
    Ahlers, Christoph M.
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok
    Gettinger, Scott N.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S365 - S366
  • [49] A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY
    Weber, J. S.
    Minor, D. R.
    D'Angelo, S. P.
    Hodi, F. S.
    Gutzmer, R.
    Neyns, B.
    Hoeller, C.
    Khushalani, N. I.
    Miller, W. H.
    Grob, J-J.
    Lao, C.
    Linette, G.
    Grossmann, K.
    Hassel, J. C.
    Lorigan, P.
    Maio, M.
    Sznol, M.
    Lambert, A.
    Yang, A.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2014, 25
  • [50] Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy
    Rizvi, N. A.
    Antonia, S. J.
    Shepherd, F. A.
    Chow, L. Q.
    Goldman, J.
    Shen, Y.
    Chen, A. C.
    Gettinger, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S32 - S32
12345